109results about "Microbiology" patented technology

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

A reagent kit, staining method, and application for combining dual immunohistochemistry with elastin fiber staining. The reagent kit includes a combination of primary antibodies, consisting of anti-CK7 and anti-CD34 monoclonal antibodies from different species, such as rabbit anti-human CK7 monoclonal antibody and mouse anti-human CD34 monoclonal antibody. By selecting CK7 and CD34 as the primary antibody combination, the growth pattern of tumor epithelium can be accurately indicated, and the proliferation and thickening of alveolar septal fibrous tissue caused by tumors can be clearly revealed, as opposed to structural changes of alveoli induced by other factors. Combined with independent Victoria blue staining, the elastin fibers of the walls of arteries and veins, as well as the pleura of the lungs, can be clearly visualized, aiding in the assessment of the integrity of elastin fibers on the lung surface and in determining the extent of tumor infiltration.

Method for single molecule localization microscopy (SMLM) based on conventional fluorescent binder probes, including primary or secondary antibodies, that are applied in a gradual stepwise fashion to a fixed biological sample. In each step of the process, a low dose of the probe is applied in solution to the fixed biological sample to sparsely label target epitopes followed by sample washing to remove the free probe. The remaining bound fluorescent probes that are sparsely distributed over the sample are then imaged until they are photobleached. The high light collection efficiency from each probe in this approach (limited only by photobleaching) enables few Ångstrom lateral resolution and few nm axial resolution. Photobleaching of the probes at the end of each step generates a clean slate for application of the next step in the process, as well as the possibility for applying one or more probes in a consecutive fashion to the same sample for serial SMLM.

The invention discloses a skeletal muscle repair method and system based on muscle satellite cell regulation and control. The method comprises the following steps: performing proliferation and differentiation correlation analysis on satellite cell steady state data and aerobic exercise intensity data to establish a proliferation regulation and control map; determining a collaborative repair time window according to the atlas, extracting difference response deviation correction parameters to form an activity correction factor, and performing repair intensity correction on the collaborative repair time window to generate a self-adaptive repair window; carrying out exercise prescription adaptation on the self-adaptive repair window, identifying a satellite cell activation regulation and control channel, obtaining activation delay time through activation efficiency mapping, and delimiting a response level according to the activation delay time to generate layered repair configuration; activation delay evaluation is conducted on layered repair configuration to determine a preferred activation mode, dynamic activation characteristics are extracted based on optimal activation time window data to form an intervention execution sequence, a skeletal muscle repair execution instruction is output in combination with an exercise prescription parameter table, and dynamic collaborative adaptation of satellite cell repair state monitoring and training scheme parameters is achieved.

The disclosure relates to methods for treating cancer or selecting subjects for cancer treatment using low PD-L1 expression as a patient biomarker prior to treatment.

Disclosed herein are biomarkers that correlate with responses to an anti-ILT4 and anti-PD-1 combination therapy. A biomarker that can differentiate responders from non-responders to this combination therapy can potentially be used to select human subjects who have a higher probability to benefit from such a combination therapy. In one embodiment, a combined positive score (CPS) for PD-L1 expression in a tumor sample from a human subject is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy. In another embodiment, a T-cell–inflamed gene expression profile (TcellinfGEP) score is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy.

The invention provides diagnostic methods for identifying individuals having a lung cancer (e.g., NSCLC) suitable for treatment a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) after adjuvant therapy (e.g., after a platinum-based adjuvant therapy) and therapeutic methods for treating lung cancer (e.g., NSCLC) in an individual identified as one who may benefit from treatment with a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the individual following an adjuvant therapy (e.g., after a platinum-based adjuvant therapy). Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, assays thereof, kits thereof, and articles of manufacture thereof) for use in identifying patients suitable for treatment and for treating lung cancer (e.g., NSCLC) in an identified individual.

A method to produce a rapid immunohistochemical detection of an antigen from a biological sample is provided. Preferably, the method may be used for rapid immunohistochemical staining of a biological sample that allows completion of the staining process in less than ten minutes, such as during a cancer removal procedure. Preferably, the method may include the steps of: depositing a section of the biological sample on a slide; permeabilizing the section of the biological sample; incubating the section of the biological sample with a secondary antibody having a detectable label; removing unbound secondary antibody from the section of the biological sample; mounting the section of the biological sample; and detecting secondary antibody bound to the section of the biological sample.

The present application describes a method for reducing background fluorescence in single molecule fluorescence in situ hybridization applications, wherein first Sudan Black B is applied to formalin-fixed, paraffin-embedded tissue sections and thereafter the single molecule fluorescence in situ hybridization application is carried out. Furthermore, there is described the use of Sudan Black B for reducing background fluorescence in single molecule fluorescence in situ hybridization applications.

The invention discloses a method for improving the dispersion degree of a sample spot edge of a liquid quality control product, which comprises the following steps: pretreating an EP tube loaded with the liquid quality control product: soaking the EP tube in a surfactant solution, directly draining water, and completely drying in a drying oven; the surfactant solution is one of a Tween-20 solution with the volume concentration of 1%-12%, a Tween-80 solution with the volume concentration of 2%-15% and a Triton-100 solution with the volume concentration of 5%-20%. The pre-treated EP tube is used for loading the liquid quality control product, so that the'coffee ring 'phenomenon can be eliminated in the subsequent sample application process of the liquid quality control product, the quality control product is dispersed more uniformly, the diameter of a sample application spot is not obviously influenced under treatment of different concentrations, and the treated liquid quality control product has the advantages of uniform sample application spot diameter and high quality. The subsequent immunohistochemical staining performance of the liquid quality control product is not influenced.

The invention provides diagnostic methods for identifying individuals having a lung cancer (e.g., NSCLC) suitable for treatment a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) after adjuvant therapy (e.g., after a platinum-based adjuvant therapy) and therapeutic methods for treating lung cancer (e.g., NSCLC) in an individual identified as one who may benefit from treatment with a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the individual following an adjuvant therapy (e.g., after a platinum-based adjuvant therapy). Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, assays thereof, kits thereof, and articles of manufacture thereof) for use in identifying patients suitable for treatment and for treating lung cancer (e.g., NSCLC) in an identified individual.

Disclosed are methods of treating of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells, wherein the subject has an isocitrate dehydrogenase mutation (IDHmut). Disclosed are methods of treating a subject comprising identifying a subject with an IDHmut; and applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells.

The present disclosure provides methods and systems for predicting a subject's diagnostic status with respect to a disease or disorder. The method may comprise staining a tooth, hair, or nail sample of the subject to produce a stained tooth sample, analyzing a fluorescence intensity spatially across the stained tooth, hair, or nail sample, and predicting a subject's diagnostic status with respect to a disease or disorder based at least in part on the analysis of the fluorescence intensity.

A method and apparatus for labeling a tissue section is provided. In certain aspects, the methods comprise labeling a tissue sample via a plurality of immunohistochemistry (IHC) assays for detection of markers for characterization of a cancer origin in an individual having a cancer of unknown primary (CUP). The disclosed IHC assays employ chromogen-based detection methods for improved sample efficiency and visualization of biomarkers. Further disclosed is an apparatus for carrying out the disclosed methods.

A method for identifying, prior to treatment, cancer patients who respond to anti-CLEVER-1 therapy, which includes administration of an agent capable of binding to common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) in a patient. In this method, the presence of PD-L1-expressing cells and CLEVER-1-expressing cells is detected in a tumor sample obtained from a cancer patient by immunohistochemical staining with a PD-L1-specific antibody and a mouse monoclonal IgG2a kappa STAB-1 antibody (clone 4G9), and the ratio of PD-L1-expressing cells from the total amount of viable cells present in the stained sample and the ratio of CLEVER-1-expressing cells within the tumor from the total amount of viable tumor cells present in the stained sample are calculated. A tumor sample with a low ratio of PD-L1-expressing cells or no PD-L1-expressing cells and a significant proportion of CLEVER-1-expressing cells within the tumor indicates that the cancer patient is responsive to anti-CLEVER-1 therapy.

The invention relates, in part, to methods and compounds for ultrastructure membrane expansion microscopy (umExM), which permits high-resolution visualization of membrane ultrastructure using light microscopy.

The present disclosure provides an antibody for predicting breast cancer prognosis and a nucleic acid encoding sequence thereof, and uses of the same. The antibody for predicting breast cancer prognosis of the present disclosure achieves the effect of predicting breast cancer prognosis through various efficacy experiments.

The present invention relates to methods and systems for detecting one or more analytes in a sample and / or for classifying a sample. In particular, the present invention relates to methods and systems which can be used to detect the analytes in real time and which rely on flowing through a microfluidic device one or more types of sensor molecule each comprising a domain that binds one or more analytes, a chemiluminescent donor domain and an acceptor domain, wherein the separation and relative orientation of the chemiluminescent donor domain and the acceptor domain, in the presence and / or absence of analyte is within ± 50% of the Forster distance.

The present invention relates to the field of oncology. It more particularly relates to a method for evaluating the prognosis or the response to a therapeutic treatment of a subject having a squamous cell carcinoma by assessing the multinucleated giant cells status of a SCC tumor of the subject. This method may be advantageously computer-implemented for ease of use in the clinic.

The invention provides a marker, a kit containing the marker, application of the marker and a use method of the marker. The marker comprises at least one selected from the group consisting of MUC1, MUC5AC, and Claudin18.2. The invention also relates to a method for preparing the marker. The marker and the kit containing the marker can be used for predicting prognosis of the intrahepatic cholangiocarcinoma, predicting the curative effect of targeted therapy and postoperative adjuvant therapy on the intrahepatic cholangiocarcinoma based on tumor expression states, and performing classified prediction on a big bile duct type and a small bile duct type of the intrahepatic cholangiocarcinoma. The disclosure also provides a method of cancer prognosis comprising detecting the expression of the marker and predicting the degree of benefit from post-operative adjuvant therapy in a subject, and / or the prognosis of cancer, particularly intrahepatic cholangiocarcinoma, in a subject. The present disclosure provides universal markers that can be used to predict the efficacy of postoperative adjuvant therapy, such as postoperative adjuvant chemotherapy, on intrahepatic cholangiocarcinoma.

The application discloses an antibody (YHWG-1) against HLA-G molecules and application, the antibody (YHWG-1) is produced by hybridoma with the preservation number of CCTCC NO:202120, using all currently known 7 HLA-G isomer molecules (HLA-G1, HLA-G2, HLA-G3, HLA-G4, HLA-G5, HLA-G6 and HLA-G7) shared, the antigen peptide (QTDRMNLQTLRGYYNQSEAS) of the 72~91 amino acid sequence in the HLA-G molecule heavy chain alpha 1 domain is immunogen.The application provides nucleotide and the amino acid sequence coded by the YHWG-1 antibody of the application, and the application also provides the application of the YHWG-1 antibody for HLA-G isomer molecule immunohistochemical, immunoblotting and flow cytometry detection.

Disclosed are methods of treating of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells, wherein the subject has an isocitrate dehydrogenase mutation (IDHmut). Disclosed are methods of treating a subject comprising identifying a subject with an IDHmut; and applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells.

Methods and compositions for accurate identification of Parkinson's disease are disclosed. More particularly, the disclosure is directed to the determination of Parkinson's disease in ante-mortem tissue samples.

The present invention relates to prognostic and therapeutic methods for the treatment of cancer (e.g., lung cancer, e.g., non-small cell lung cancer (NSCLC)) using expression levels of tumor-associated macrophage (TAM) and regulatory T cell (Treg) genes. In particular, the invention provides methods for patient selection and treatment.

The invention discloses an immunohistochemical reaction system and method, relates to the technical field of biomedical treatment, and mainly aims to solve the problem of poor staining effect of existing immunohistochemical. Comprising a tissue sample incubation area, a mechanical arm, a glass slide clamping piece and a controller, the tissue sample incubation area comprises multiple layers of reaction trays, each reaction tray comprises a plurality of glass slide heating areas, and heaters aligned with glass slide grooves in the glass slide clamping piece are arranged in the glass slide heating areas; the reaction tray enters and exits the tissue sample incubation area through conveying equipment arranged on the two sides of the tissue sample incubation area; the controller is used for determining a target glass slide identifier of the target tissue glass slide and driving the mechanical arm to place the glass slide clamping piece bearing the target tissue glass slide in the target glass slide heating area according to the target glass slide identifier; and controlling a target heater corresponding to the target glass slide heating area to heat according to a preset heating threshold.

The present application discloses an immunohistochemical reaction system and method, which relates to the field of biomedical technology and is primarily intended to address the problem of poor immunohistochemical staining effects in existing immunohistochemical processes. The system comprises: a tissue sample incubation area, a robotic arm, a slide holder, and a controller. The tissue sample incubation area includes a multi-layer reaction tray, the reaction tray includes multiple slide heating zones, the slide heating zones are provided with heaters aligned with slide slots on the slide holder, and the reaction trays enter and exit the tissue sample incubation area via conveying devices provided on both sides of the tissue sample incubation area. The controller is configured to determine a target slide identifier of a target tissue slide and, in accordance with the target slide identifier, drive the robotic arm to place the slide holder carrying the target tissue slide into the target slide heating zone; and control the target heater corresponding to the target slide heating zone to heat the sample according to a preset heating threshold.

A method for detecting the amount of CDH17 protein in a sample from a subject, the method comprising: contacting the sample with a buffer at a temperature of at least 98°C to provide a treated sample, contacting the treated sample with a capture antibody having a binding affinity to CDH17, wherein any exposed CDH17 expressing epitope in the treated sample is configured to bind to the capture antibody to provide a bound sample, contacting the bound sample with a detection molecule to provide a detection sample, wherein the detection molecule comprises a biocompatible enzyme conjugated to a secondary antibody having a binding affinity to the capture antibody, reacting the detection sample with a 3,3'Diamonobenzidine chromogen to provide an oxidized substrate, and determining the amount of CDH17 protein in the sample based on the amount of oxidized substrate.

The invention discloses application of Dectin-1 as a biomarker in preparation of a renal fibrosis diagnostic reagent or kit, and belongs to the field of biological medicine. And Dectin-1 is a member of a pattern recognition receptor C-type lectin family. According to the invention, Dectin-1 immunofluorescent staining is carried out on kidney tissues of patients with chronic kidney diseases, and observation shows that the number of Dectin-1 + cells in fibrosis kidneys is more. Dectin-1 immunofluorescence staining is further carried out in the kidney tissue of the patient with the IgA nephropathy, and it is found that the number of Dectin-1 + cells in the kidney tissue of the patient with the IgA nephropathy is in positive correlation with the renal fibrosis degree. The results show that the reagent for detecting the expression level of the Dectin-1 in the kidney cells can be used for preparing the kit for diagnosing the kidney fibrosis, and the diagnosis result has high sensitivity and specificity.